Deutsche Bank AG lifted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 20.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 296,820 shares of the medical instruments supplier’s stock after acquiring an additional 50,511 shares during the quarter. Deutsche Bank AG owned 0.40% of West Pharmaceutical Services worth $89,747,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of WST. Bank of America Corp DE increased its position in shares of West Pharmaceutical Services by 36.7% during the first quarter. Bank of America Corp DE now owns 639,632 shares of the medical instruments supplier’s stock valued at $262,703,000 after acquiring an additional 171,554 shares during the last quarter. Fiera Capital Corp increased its position in West Pharmaceutical Services by 3,441.3% in the first quarter. Fiera Capital Corp now owns 86,762 shares of the medical instruments supplier’s stock worth $35,634,000 after buying an additional 84,312 shares during the last quarter. Vanguard Group Inc. increased its position in West Pharmaceutical Services by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,716,312 shares of the medical instruments supplier’s stock worth $3,579,876,000 after buying an additional 82,459 shares during the last quarter. ProShare Advisors LLC increased its position in West Pharmaceutical Services by 15.9% in the second quarter. ProShare Advisors LLC now owns 490,325 shares of the medical instruments supplier’s stock worth $148,260,000 after buying an additional 67,170 shares during the last quarter. Finally, Aaron Wealth Advisors LLC purchased a new stake in West Pharmaceutical Services in the first quarter worth $159,000. 91.98% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the company. KeyCorp decreased their target price on West Pharmaceutical Services from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, October 28th. StockNews.com assumed coverage on West Pharmaceutical Services in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Finally, Bank of America cut West Pharmaceutical Services from a “buy” rating to a “neutral” rating and reduced their price target for the company from $385.00 to $250.00 in a research report on Friday, October 28th.
West Pharmaceutical Services Price Performance
West Pharmaceutical Services Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 16th. Investors of record on Wednesday, November 9th were paid a dividend of $0.19 per share. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.18. The ex-dividend date was Tuesday, November 8th. This represents a $0.76 annualized dividend and a yield of 0.34%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 9.17%.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.